The Pentagon Wants Dual-Use Innovation. Patent Law Might Punish It.

Key Takeaways

• Delaware court narrows Section 1498 immunity to direct government benefit
• Moderna settlement totals $2.25 billion, $1.3 b contingent
• Dual‑use “neoprime” firms face heightened patent litigation risk
• Congress may amend Section 1498 in FY2027 NDAA
• Federal Circuit decision will set nationwide precedent for defense tech

Summary

The Delaware federal court rejected Moderna’s claim that Section 1498 immunity shielded its COVID‑19 vaccine sales, holding that the statute only protects products that directly benefit the government. The ruling coincides with a $2.25 billion settlement between Moderna and Arbutus, including a $1.3 billion contingent payment tied to the appellate decision. Legal analysts warn that the narrow interpretation could expose “neoprime” defense startups, which sell dual‑use technologies to both military and commercial markets, to costly patent suits. Congress is drafting the FY 2027 National Defense Authorization Act but has not yet addressed the patent‑immunity gap.

Pulse Analysis

Section 1498 was born out of World‑I urgency, granting contractors a blanket shield from patent lawsuits when they produce items "for the Government and with its consent." Over the decades, courts have stretched the language to cover foreign‑made components and even inducement claims, making the provision a cornerstone of defense procurement risk management. The statute’s purpose was to keep litigation from choking wartime production, a goal that still resonates as the Pentagon leans on private innovators for next‑generation capabilities.

The recent Delaware decision upended that tradition by insisting that the benefit must flow to the government itself, not merely to the public. Moderna’s COVID‑19 vaccine, though purchased for $8.2 billion by the United States, was administered to civilians, prompting the court to deny immunity for the bulk of sales. The $2.25 billion settlement—$950 million upfront and $1.3 billion pending appeal—highlights the financial stakes. For neoprime firms like Anduril or Palantir, whose platforms serve both military bases and commercial clients, the ruling threatens to expose a core revenue stream to patent infringement claims, potentially raising capital costs and slowing innovation.

Policymakers are already wrestling with this gap as they shape the FY 2027 National Defense Authorization Act. While recent NDAA language eases procurement barriers for non‑traditional contractors, it stops short of clarifying patent immunity. A targeted amendment could restore the broad protection that encourages dual‑use development, directing compensation claims to the federal government instead of private firms. Until Congress acts—or the Federal Circuit issues a definitive ruling—defense innovators must reassess contract structures, consider additional patent insurance, and closely monitor litigation trends to safeguard their investment pipelines.